» Articles » PMID: 32239172

Hereditary Hemochromatosis Disrupts Uric Acid Homeostasis and Causes Hyperuricemia Via Altered Expression/activity of Xanthine Oxidase and ABCG2

Overview
Journal Biochem J
Specialty Biochemistry
Date 2020 Apr 3
PMID 32239172
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Hereditary hemochromatosis (HH) is mostly caused by mutations in the iron-regulatory gene HFE. The disease is associated with iron overload, resulting in liver cirrhosis/cancer, cardiomegaly, kidney dysfunction, diabetes, and arthritis. Fe2+-induced oxidative damage is suspected in the etiology of these symptoms. Here we examined, using Hfe-/- mice, whether disruption of uric acid (UA) homeostasis plays any role in HH-associated arthritis. We detected elevated levels of UA in serum and intestine in Hfe-/- mice compared with controls. Though the expression of xanthine oxidase, which generates UA, was not different in liver and intestine between wild type and Hfe-/- mice, the enzymatic activity was higher in Hfe-/- mice. We then examined various transporters involved in UA absorption/excretion. Glut9 expression did not change; however, there was an increase in Mrp4 and a decrease in Abcg2 in Hfe-/- mice. As ABCG2 mediates intestinal excretion of UA and mutations in ABCG2 cause hyperuricemia, we examined the potential connection between iron and ABCG2. We found p53-responsive elements in hABCG2 promoter and confirmed with chromatin immunoprecipitation that p53 binds to this promoter. p53 protein was reduced in Hfe-/- mouse intestine. p53 is a heme-binding protein and p53-heme complex is subjected to proteasomal degradation. We conclude that iron/heme overload in HH increases xanthine oxidase activity and also promotes p53 degradation resulting in decreased ABCG2 expression. As a result, systemic UA production is increased and intestinal excretion of UA via ABCG2 is decreased, causing serum and tissue accumulation of UA, a potential factor in the etiology of HH-associated arthritis.

Citing Articles

Ferric Ammonium Citrate Reduces Claudin-5 Abundance and Function in Primary Mouse Brain Endothelial Cells.

Runwal P, Pyun J, Newman S, Mawal C, Bush A, Koehn L Pharm Res. 2025; 42(2):319-334.

PMID: 39939558 PMC: 11880181. DOI: 10.1007/s11095-025-03826-2.


Sigma Receptors: Novel Regulators of Iron/Heme Homeostasis and Ferroptosis.

Nguyen N, Jaramillo-Martinez V, Mathew M, Suresh V, Sivaprakasam S, Bhutia Y Int J Mol Sci. 2023; 24(19).

PMID: 37834119 PMC: 10572259. DOI: 10.3390/ijms241914672.


Reduction in ABCG2 mRNA Expression in Human Immortalised Brain Microvascular Endothelial Cells by Ferric Ammonium Citrate is Mediated by Reactive Oxygen Species and Activation of ERK1/2 Signalling.

Newman S, Short J, Nicolazzo J Pharm Res. 2022; 40(3):651-660.

PMID: 36539667 DOI: 10.1007/s11095-022-03458-w.


Polycystic ovary syndrome and iron overload: biochemical link and underlying mechanisms with potential novel therapeutic avenues.

Mathew M, Sivaprakasam S, Phy J, Bhutia Y, Ganapathy V Biosci Rep. 2022; 43(1).

PMID: 36408981 PMC: 9867939. DOI: 10.1042/BSR20212234.


Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk: 2021 update.

Borghi C, Domienik-Karlowicz J, Tykarski A, Widecka K, Filipiak K, Jaguszewski M Cardiol J. 2021; 28(1):1-14.

PMID: 33438180 PMC: 8105060. DOI: 10.5603/CJ.a2021.0001.


References
1.
Kim J, Lee C, Bonifant C, Ressom H, Waldman T . Activation of p53-dependent growth suppression in human cells by mutations in PTEN or PIK3CA. Mol Cell Biol. 2006; 27(2):662-77. PMC: 1800819. DOI: 10.1128/MCB.00537-06. View

2.
Tanner C, Boocock J, Stahl E, Dobbyn A, Mandal A, Cadzow M . Population-Specific Resequencing Associates the ATP-Binding Cassette Subfamily C Member 4 Gene With Gout in New Zealand Māori and Pacific Men. Arthritis Rheumatol. 2017; 69(7):1461-1469. PMC: 5984252. DOI: 10.1002/art.40110. View

3.
Shen J, Sheng X, Chang Z, Wu Q, Wang S, Xuan Z . Iron metabolism regulates p53 signaling through direct heme-p53 interaction and modulation of p53 localization, stability, and function. Cell Rep. 2014; 7(1):180-93. PMC: 4219651. DOI: 10.1016/j.celrep.2014.02.042. View

4.
So A, Martinon F . Inflammation in gout: mechanisms and therapeutic targets. Nat Rev Rheumatol. 2017; 13(11):639-647. DOI: 10.1038/nrrheum.2017.155. View

5.
Ristic B, Sikder M, Bhutia Y, Ganapathy V . Pharmacologic inducers of the uric acid exporter ABCG2 as potential drugs for treatment of gouty arthritis. Asian J Pharm Sci. 2020; 15(2):173-180. PMC: 7193448. DOI: 10.1016/j.ajps.2019.10.002. View